Nama's AI scorecard currently rates Axogen Hold (4.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is AXGN's P/E ratio?

Axogen trades at a trailing price-to-earnings ratio of 106.4.

When does AXGN report earnings?

Axogen's next scheduled report is on Feb 23, 2027. Analysts expect EPS of $0.15.

What is the AXGN price target?

The median analyst price target from 11 analysts is $60.00, with a range of $56.00 – $65.00.

Is AXGN Shariah compliant?

Nama's AAOIFI-style screen reads Axogen as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Axogen (AXGN)

Healthcare · Medical Devices · NASDAQ

Axogen (AXGN) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $2.99B, a trailing price-to-earnings ratio of 106.4 and a free-cash-flow yield of -0.2%. Over the most recent reported fiscal year, revenue grew 20.2% and free cash flow per share fell 41880.6%. Nama's AI scorecard rates it Hold, 4.5 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Hold · 4.5/10

The sections balance. As of Nov 7, 2026.

Momentum

Rising · +50.2% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-5.5%

How far the last close sits under the highest price of the past five years.

Market cap	$2.99B
Trailing P/E	106.4
Price / book	10.4
Price / sales	11.2
FCF yield	-0.2%
Dividend yield	—
Gross margin	74.6%
Operating margin	-5.1%
Net margin	-13.4%
Revenue growth (YoY)	+20.2%
Revenue growth (3-yr annual)	+17.6%
EPS growth (YoY)	+123.1%
FCF/share growth (YoY)	-41880.6%
Beta	1.2
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Devices

AXGN earnings

Next report: Feb 23, 2027 (Q4 2026, EPS estimate $0.15). Beat the EPS estimate in 1 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 28, 2026	$0.21	$0.13	+61.5%	$75.83M
Q2 2026	Jul 29, 2026	$0.12	$0.12	+0.0%	$69.73M
Q1 2026	Apr 28, 2026	$0.07	$0.07	+0.0%	$61.46M
Q4 2025	Feb 24, 2026	$0.07	$0.10	-30.0%	$59.90M

AXGN analyst price target

Median target $60.00 from 11 analysts, ranging $56.00 – $65.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7

Explore live AXGN data on Nama Insights →

AXGN FAQ

Is AXGN a buy?: Nama's AI scorecard currently rates Axogen Hold (4.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is AXGN's P/E ratio?: Axogen trades at a trailing price-to-earnings ratio of 106.4.
When does AXGN report earnings?: Axogen's next scheduled report is on Feb 23, 2027. Analysts expect EPS of $0.15.
What is the AXGN price target?: The median analyst price target from 11 analysts is $60.00, with a range of $56.00 – $65.00.
Is AXGN Shariah compliant?: Nama's AAOIFI-style screen reads Axogen as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.